Organic Active Ingredients TRIZ Cases

Substituted heteroaryl compounds stabilize hypoxia inducible factor to activate protective gene expression, addressing tissue damage from ischemia.

Bioadhesive slow-release carriers deliver clonidine to oral mucosa, reducing inflammatory pain severity and duration in mucositis patients.

A rifaximin alpha formulation employs a wicking agent to maintain water activity between 0.005 and 0.09, preventing polymorphic conversion into delta forms.

A nutritional composition containing casein-derived peptides with a molar mass greater than 500 Daltons modulates immune responses.

Indole derivatives correct aberrant splicing defects in nuclear lamin A genes, reducing cellular toxicity while maintaining treatment effectiveness.

Lipid nanoparticles encapsulate siRNA for targeted pulmonary delivery, avoiding viral vector toxicity and immunogenicity.

Double-stranded RNA targets GNAQ mRNA via RNA interference, resolving insufficient inhibition effectiveness of conventional methods.

Milvexian selectively inhibits activated Factor XIa, reducing thrombosis risk without increasing bleeding incidence.

Inhibiting DUSP6 restores autophagic flux and structural repair in the retinal layer despite oxidative stress damage.

A partially unfolded alpha-lactalbumin and fatty acid complex selectively destroys gastrointestinal tumor cells.

Daily conjugated linoleic acid administration reduces fat mass while increasing lean body mass, addressing obesity and muscle weakness in Prader-Willi syndrome.

Monitoring bone mineralization analytes guides personalized alkaline phosphatase replacement therapy adjustments.

Local OGFR antagonist delivery via hydrogel carriers achieves selective tumor cell cytotoxicity while sparing normal tissue from systemic toxicity.

A novel synthesis method for zilpaterol using alpha-halogenation of ketones followed by nucleophilic substitution and hydride reduction.

A GPX4 inhibitor combined with Bcl-2 inhibitors induces ferroptosis, overcoming treatment resistance in elderly acute myeloid leukemia patients.

Fractionated CD25-ADC dosage regimes divide total doses into multiple partial administrations.

Fucoidan mediates between 5-fluorouracil and healthy tissue, reducing nausea and fatigue while preserving anticancer efficacy.

Crystallization controls phase transitions to transform unstable form-III crystals into thermodynamically stable form-I and form-II polymorphs.

Selective phenyl piperazine derivatives target postsynaptic 5-HT1A receptors, reducing side effects like weight gain associated with non-selective SSRIs.

Administering a SMAD4 inhibitor normalizes astrocytic differentiation and potassium homeostasis, addressing impaired K+ channel function in schizophrenia.

Formula I compounds inhibit arginine methyltransferases, addressing the lack of effective inhibitors for treating associated disorders.

Specific nucleic acid oligomers bind SSB1 and THOC4 proteins to inhibit DNA repair, reducing tumor growth while sparing normal cells.

Tetra-aza-heterocycles address ineffective kinase inhibition by targeting PI3-kinases to treat diseases with excessive cell proliferation.

Segmented cytokine protocols extend neutrophil lifespan and boost tumor-killing activity, overcoming short in vitro viability.

Heterocyclic compounds inhibit the PD-1/PD-L1 protein interaction, restoring T-cell responses against cancer immune evasion.

Developing Form F hemisuccinate monohydrate prevents polymorphic interconversion and stability issues in pharmaceutical applications.

Administering a specific PCSK9 inhibitor antibody reduces atherosclerotic plaque formation by up to 90% despite existing lipid-modifying therapies.

Tromethamine buffers pH and inert gas purges oxygen to prevent oxidative degradation of Pemetrexed.

Antcin K compounds activate FGF21 and RDH10 receptors, overcoming poor pharmacokinetics and side effects of polypeptide analogues.

CTK7A reduces oral cancer progression by inhibiting p300/CBP and PCAF enzymes, lowering hyperacetylation and inducing senescence.

Segmenting PI3K inhibitors by isoform specificity resolves the trade-off between broad adaptability and reliable disease treatment.

Retinol-like eye compositions boost corneal hyaluronic acid to sustain tear film stability and reduce dry eye symptoms.

Albumin-bound rapamycin nanoparticles deliver anti-proliferative drugs directly into the blood vessel wall using a catheter with deployable needles.

Targeting IL-13 signaling bypasses slow immunomodulators and steroid side effects for faster ulcerative colitis relief.

Hydrocolloids stabilize aqueous nasal suspensions of mometasone and olopatadine, preventing phase separation during storage.

Ultrasonic disruption of sonochemically-active microspheres releases encapsulated gas to facilitate ABCA1 plasmid delivery, increasing plasma HDL-c levels.

Alcohol protection prevents by-product formation during partial reduction, eliminating complex purification and boosting production yield.

Benzofuranyl indolylmaleimides inhibit GSK-3 while crossing the blood-brain barrier to treat neurodegenerative disorders.

A gamma-aminobutyric acid composition enhances endurance by increasing muscle capillaries and glycogen storage.

Tartaric acid maintains a pH below 7 in tacrolimus formulations, reducing 8-epitacrolimus formation and improving bioavailability.

A hydrogel patch composed of fibrin and laminin creates a regenerative environment for neural stem cells.

Artesunate increases transferrin receptor 1 palmitoylation, correcting impaired receptor recycling and reducing pathological iron accumulation in the brain.

Characterized crystal forms resolve stability and bioavailability contradictions in cholinesterase inhibitor development.

Fenoterol analogues cross the blood-brain barrier to target beta2-adrenergic receptors, treating glioblastomas where standard agents fail.

Testing serum levels and adjusting mifepristone doses prevents subtherapeutic blood concentrations in Cushing's syndrome patients.

Midostaurin reduces bullae and normalizes serum tryptase levels in pediatric systemic mastocytosis.

Merges targeted therapy with chemotherapy to overcome resistance and improve survival outcomes.

A supercritical CO2 fluid extracted enhanced lipidosterolic extract of Serenoa repens provides a stable composition for hair health and growth.

Compounds bind to the SOS hydrophobic pocket to enhance nucleotide exchange, increasing Ras-GTP levels and perturbing MAPK signaling for cancer cell death.

Tocopherol polyethylene glycol micelles encapsulate vitamin D to boost serum levels without toxicity risks from high doses.

Phosphaphenalene-gold(I) complexes overcome blood-brain barrier limitations and tumor resistance by inhibiting thioredoxin reductase to induce apoptosis.

Crystalline form I of the hydrogen sulfate salt of a bcl-2 inhibitor stabilizes the active pharmaceutical ingredient through controlled polar medium crystallization.

Macrocyclic inhibitors with flexible quinoxalines bind constrained protease regions, reducing drug resistance across genotypes.

Calculating glyceryl triphenylbutyrate dosage by body surface area to optimize nitrogen scavenging.

Angiopep-1 conjugates transport Taxol across the blood-brain barrier to bypass P-glycoprotein efflux pumps in brain metastases.

Form I of the HDAC inhibitor maintains stability under high humidity by limiting moisture absorption to less than 0.2 percent.

A hyaluronic acid-albumin nanoformulation maintains even particle size distribution through specific conjugation ratios.

Segmented biocompatible polymer layers establish permeable pathways for therapeutic agents to prevent prolonged retention of unstable drugs.

Optimized extraction parameters achieve high arctigenin content and controlled ratios, treating pancreatic cancer refractory to gemcitabine.

Modulating ErbB-2 signaling reactivates endogenous cardiomyocyte proliferation, eliminating the need for exogenous stem cells in cardiac regeneration.

RS-79948-197 antagonizes stereotypies and hypermotility while avoiding clozapine-induced neutropenia.

Formula I heterocyclic compounds inhibit viral replication, addressing limited efficacy and safety concerns in high-risk patient populations.

AMD3100 conjugates modify T-cells to penetrate the CXCL12 fugetactic wall, restoring directional guidance for cancer immunotherapy.

RNA regulators modulate FOXO1 and ETV6 to reverse cellular senescence, addressing dysregulated splicing in age-related diseases.

Splicing modulating agents induce aberrant splicing events to produce tumor neoantigens, expanding the patient population benefiting from immunotherapy.

Segmenting the triterpenoid core from heteroaryl substituents at position 17 boosts nitric oxide inhibition while managing synthesis complexity.

Isolated S(+)-MA5 enantiomer raises NAD+ levels while avoiding R(-) form cytotoxicity.

Novel heterocyclic compounds selectively inhibit prolyl-tRNA synthetase activity, reducing toxicity and genotoxicity associated with existing inhibitors.

Lipid-coated mesoporous silica nanoparticles encapsulate antiviral compounds to enhance solubility and stability.

Novel heterocyclic amide compounds inhibit the trehalose monomycolate transporter MmpL3 to deliver potent antimycobacterial activity.

Composite contrast agents combine chelator groups and binding moieties to resolve specificity and efficiency contradictions in metal ion detection.

A suplatast tosilate formulation combines immediate and extended release components for once or twice daily administration.

Segmented dsRNA agents inhibit ANGPTL4 expression to treat chronic fibro-inflammatory liver diseases.